Pharma News

This acquisition comes at a pivotal time for AbbVie, which has spent over $20 billion since 2023 to counter the patent expiration of its blockbuster drug Humira.

The global biopharma sector navigated a challenging yet active first half of 2025, completing 32 mergers and acquisitions despite significant regulatory and geopolitical uncertainties.

The United States announced a significant shift in its trade policy with Vietnam, reducing planned tariffs on Vietnamese exports to 20%, down from the initially proposed 46%, just days before a critical July 9 deadline.

The United States has lifted restrictions on ethane exports to China, reinstating a critical trade flow that had been halted since June.

China has expressed a willingness to engage with the U.S. on key trade policy challenges, including tariffs, subsidies, and industrial policies, as part of discussions to reform the World Trade Organization (WTO).

China has announced a five-year extension of anti-dumping duties on certain stainless steel products imported from the European Union, United Kingdom, South Korea, and Indonesia, aiming to safeguard its domestic manufacturers.

Chinese pharmaceutical company Innogen is accelerating efforts to complete clinical trials for its weight-loss drug efsubaglutide alfa, aiming to tap into the growing demand for obesity treatments in China.

On July 1, 2025, NHU (Zhejiang NHU Co., Ltd.) released its 2025 interim earnings forecast, expecting net profit attributable to shareholders to hit 33 billion to 37.5 billion yuan, marking a 50%-70% year-on-year growth.

The NATO Innovation Fund has made its first major investment by co-leading a $35 million funding round for UK-based Portal Biotech.

Biological E, an Indian pharmaceutical manufacturer, has partnered with China’s Recbio to produce and commercialize the REC603 HPV9 vaccine, marking a significant step in combating HPV-related cancers.

Novo Nordisk’s weight-loss drug Wegovy, once hailed as a breakthrough obesity treatment, is facing stiff competition from Eli Lilly’s Zepbound, highlighting critical missteps in Novo’s market strategy.

San Francisco: High costs of obesity medicines are driving Americans to a growing "gray market," where individuals make their own weight-loss drugs using cheap, unregulated active ingredients shipped from China.

Torrent Pharma is closing in on a $2.4 billion acquisition of JB Chemicals and Pharmaceuticals, marking its biggest deal yet.

New Delhi: Indian Contract Research and Development and Manufacturing Organizations (CRDMOs) are gaining momentum as global pharmaceutical companies expand operations geographically, according to a report by Jefferies.

Washington: A U.S. senator has launched an investigation into GlaxoSmithKline's (GSK) decision to discontinue the Flovent HFA inhaler, a widely used asthma treatment for children.

Nagpur: In a groundbreaking development, new medicines are helping 1 in 4 heart failure patients regain normal heart function, according to experts at the Annual ECHO Nagpur 2025 Conference.

Daiichi Sankyo and AstraZeneca announced that the FDA had approved Datopotamab Deruxtecan for its second indication, targeting locally advanced or metastatic EGFR-mutated non-small cell lung cancer (NSCLC) in adult patients who have previously undergone E

On June 20, the UK House of Commons narrowly passed the Assisted Dying Bill with a vote of 314 in favor to 291 against, following nearly four hours of heated debate.

The recent move of Shan Guohong, former Takeda Senior Vice President and China President, to BeiGene has drawn significant industry attention.

Merck announced that its novel non-nucleoside cytomegalovirus (CMV) inhibitor, Letermovir, in both tablet and injectable forms, has been approved by the National Medical Products Administration (NMPA) for use in children aged 6 months and above.